Avalo Therapeutics (AVTX) to Release Earnings on Monday

Key Points

• Avalo Therapeutics will report Q1 2026 results before the market on May 11; analysts expect EPS of ($1.1776) and revenue of about $0.052M, with an earnings call scheduled for May 15 at 9:30 AM ET.
• Company insiders sold a total of 63,015 shares (~$987,326) in the past three months, leaving insider ownership at just 4.46%.
• Analysts collectively rate AVTX a "Moderate Buy" with an average price target of $44.83, even as consensus forecasts expect roughly -$4 EPS this fiscal year and -$3 EPS next year.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) is expected to post its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect Avalo Therapeutics to post earnings of ($1.1776) per share and revenue of $0.0520 million for the quarter. Investors may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last posted its quarterly earnings results on Monday, March 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.54) by $1.17. The business had revenue of $0.06 million for the quarter, compared to analysts' expectations of ($0.21) million. On average, analysts expect Avalo Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Avalo Therapeutics Price Performance

NASDAQ AVTX traded up $0.07 during trading on Monday, hitting $13.78. 52,775 shares of the company's stock traded hands, compared to its average volume of 606,242. The stock has a fifty day moving average of $15.29 and a two-hundred day moving average of $16.22. Avalo Therapeutics has a 12-month low of $3.39 and a 12-month high of $20.72. The firm has a market cap of $367.99 million, a P/E ratio of -2.39 and a beta of 0.78.

Insider Transactions at Avalo Therapeutics

In related news, insider Mittie Doyle sold 25,492 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $16.15, for a total value of $411,695.80. Following the completion of the transaction, the insider directly owned 3,622 shares of the company's stock, valued at $58,495.30. This represents a 87.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Christopher Ryan Sullivan sold 8,458 shares of the stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $13.09, for a total transaction of $110,715.22. Following the completion of the transaction, the chief financial officer directly owned 8,880 shares of the company's stock, valued at approximately $116,239.20. The trade was a 48.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 63,015 shares of company stock valued at $987,326. 4.46% of the stock is owned by insiders.

Hedge Funds Weigh In On Avalo Therapeutics

Institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP bought a new position in Avalo Therapeutics in the third quarter worth about $143,000. Boothbay Fund Management LLC bought a new position in Avalo Therapeutics in the second quarter worth about $56,000. Jump Financial LLC bought a new position in Avalo Therapeutics in the fourth quarter worth about $238,000. Persistent Asset Partners Ltd bought a new position in Avalo Therapeutics in the fourth quarter worth about $274,000. Finally, Hudson Bay Capital Management LP bought a new position in Avalo Therapeutics in the fourth quarter worth about $305,000. 87.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on AVTX shares. Wolfe Research started coverage on shares of Avalo Therapeutics in a research report on Thursday, April 9th. They set an "outperform" rating and a $48.00 price target for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Avalo Therapeutics in a research report on Wednesday, April 8th. BTIG Research restated a "buy" rating and set a $40.00 price target on shares of Avalo Therapeutics in a research report on Monday, April 13th. Guggenheim started coverage on shares of Avalo Therapeutics in a research report on Monday, February 2nd. They set a "buy" rating and a $50.00 price target for the company. Finally, Wall Street Zen upgraded shares of Avalo Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Sunday, March 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $44.83.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.